Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach & drug discovery capabilities to develop its products.
IPO Date: March 21, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $140.87M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.92 | 2.22%
Avg Daily Range (30 D): $0.20 | 2.75%
Avg Daily Range (90 D): $0.19 | 3.03%
Institutional Daily Volume
Avg Daily Volume: .19M
Avg Daily Volume (30 D): .16M
Avg Daily Volume (90 D): .15M
Trade Size
Avg Trade Size (Sh.): 72
Avg Trade Size (Sh.) (30 D): 69
Avg Trade Size (Sh.) (90 D): 67
Institutional Trades
Total Inst.Trades: 2,597
Avg Inst. Trade: $1.8M
Avg Inst. Trade (30 D): $.56M
Avg Inst. Trade (90 D): $.6M
Avg Inst. Trade Volume: .04M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.92M
Avg Closing Trade (30 D): $.56M
Avg Closing Trade (90 D): $.61M
Avg Closing Volume: 38.46K
   
News
Jun 11, 2025 @ 9:07 PM
FDA Expands AbbVie's Mavyret Label To Include Acut...
Source: Vandana Singh
Nov 4, 2024 @ 6:00 PM
Urticaria Clinical Trial Pipeline Accelerates: 20+...
Source: Delveinsight
May 6, 2024 @ 9:10 PM
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Top...
Source: Zacks Equity Research
Feb 7, 2024 @ 10:10 PM
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lag...
Source: Zacks Equity Research
Jan 5, 2024 @ 8:09 AM
Strength Seen in Enanta Pharmaceuticals (ENTA): Ca...
Source: Zacks Equity Research
Financials
  TTM Q2 2025 Q1 2025
Basic EPS $-1.06 $-1.05
Diluted EPS $-1.06 $-1.05
Revenue $ $ 14.93M $ 16.96M
Gross Profit $ $ $
Net Income / Loss $ -96.42M $ -22.64M $ -22.29M
Operating Income / Loss $ $ -24.53M $ -23.54M
Cost of Revenue $ $ $
Net Cash Flow $ $ -24.74M $ 47.12M
PE Ratio